Astra’s radiopharma Fusion
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Point’s big Splash falls short
Crossover hits overall survival, pouring doubts on the group’s deal hopes.
ESMO 2023 – red flags for PSMAfore
The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.
